TuHURA Biosciences’ (HURA) “Market Outperform” Rating Reiterated at Citizens Jmp

Citizens Jmp reaffirmed their market outperform rating on shares of TuHURA Biosciences (NASDAQ:HURA) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Several other equities research analysts have also recently issued reports on HURA. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Citigroup began coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating for the company. Finally, Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Price Performance

HURA opened at $2.22 on Tuesday. The company’s 50-day simple moving average is $2.29 and its two-hundred day simple moving average is $2.06. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.15 and a current ratio of 0.18. The stock has a market capitalization of $141.48 million, a P/E ratio of -4.11 and a beta of -0.01. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. As a group, analysts predict that TuHURA Biosciences will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of TuHURA Biosciences during the 3rd quarter valued at about $26,000. JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences in the 2nd quarter worth approximately $27,000. Wells Fargo & Company MN raised its stake in TuHURA Biosciences by 109.0% during the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after acquiring an additional 19,931 shares during the period. Invesco Ltd. bought a new stake in TuHURA Biosciences during the 2nd quarter worth approximately $30,000. Finally, Goldman Sachs Group Inc. purchased a new position in TuHURA Biosciences during the fourth quarter valued at approximately $30,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.